Allosteric Modulation
Explore how drugs at allosteric sites fine-tune receptor activity without competing at the active site.
## Introduction
Allosteric modulators bind to sites on a protein that are topographically distinct from the orthosteric (active/endogenous ligand) site. Rather than directly activating or blocking the receptor, they modify the receptor's response to its endogenous ligand, offering finer pharmacological control with several inherent safety advantages over orthosteric drugs.
## Types of Allosteric Modulators
**Positive allosteric modulators (PAMs)** enhance the effect of the orthosteric ligand by increasing its affinity, efficacy, or both. Benzodiazepines are PAMs at GABAA receptors—they increase the frequency of chloride channel opening, but only when GABA itself is bound. Without GABA, benzodiazepines are inactive.
**Negative allosteric modulators (NAMs)** reduce orthosteric ligand activity without fully blocking the receptor. Maraviroc is a NAM of the CCR5 chemokine receptor, preventing HIV envelope protein gp120 from engaging CCR5 by altering receptor conformation.
**Silent (neutral) allosteric modulators (SAMs)** bind the allosteric site without affecting orthosteric signaling but competitively block PAM or NAM binding. They serve primarily as pharmacological research tools.
## Advantages Over Orthosteric Drugs
Allosteric sites are less evolutionarily conserved than orthosteric sites across receptor subtypes, enabling greater subtype selectivity with fewer off-target effects. PAMs preserve the temporal and spatial pattern of endogenous signaling because they only act when the natural ligand is present—they amplify physiological signaling rather than replacing it.
Allosteric modulators also have a built-in ceiling effect: once all allosteric sites are saturated, further dosing produces no additional modulation. This ceiling limits overdose toxicity, a significant advantage for benzodiazepines over barbiturates.
## Probe Dependence
An allosteric modulator's effect can differ depending on which orthosteric ligand is present—a phenomenon called probe dependence. A PAM for one agonist may be neutral or even a NAM for a different agonist at the same receptor. This complicates drug development but also enables pathway-selective pharmacology.
## Clinical Examples
- **Benzodiazepines** (diazepam): PAM at GABAA for anxiety, insomnia, and seizures
- **Cinacalcet**: PAM at calcium-sensing receptor for secondary hyperparathyroidism
- **Mavoglurant**: NAM at mGluR5, investigated for fragile X syndrome
## Key Takeaways
- Allosteric modulators bind sites topographically distinct from the orthosteric pocket
- PAMs enhance and NAMs reduce the endogenous ligand's effect
- They offer superior subtype selectivity, ceiling effects, and preserved signaling patterns
- Probe dependence means effects vary with the specific orthosteric ligand present